Miproxifene phosphate
Miproxifene Phosphate[edit | edit source]
Miproxifene phosphate is a selective estrogen receptor modulator (SERM) that has been investigated for its potential use in the treatment of breast cancer. It is a derivative of the nonsteroidal antiestrogen tamoxifen, which is widely used in the management of estrogen receptor-positive breast cancer.
Mechanism of Action[edit | edit source]
Miproxifene phosphate functions by binding to estrogen receptors in target tissues, such as breast tissue, and modulating their activity. As a SERM, it can act as an estrogen receptor antagonist in breast tissue, thereby inhibiting the proliferative action of estrogen on breast cancer cells. This mechanism is similar to that of tamoxifen, but miproxifene phosphate has been designed to have improved efficacy and reduced side effects.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of miproxifene phosphate involves its absorption, distribution, metabolism, and excretion. After administration, it is absorbed and converted into its active form, miproxifene, which then exerts its effects on estrogen receptors. The drug is metabolized primarily in the liver and excreted via the urinary system.
Clinical Development[edit | edit source]
Miproxifene phosphate has undergone various stages of clinical trials to evaluate its safety and efficacy in the treatment of breast cancer. These studies aim to compare its performance with existing therapies, such as tamoxifen and other SERMs, in terms of tumor response, progression-free survival, and overall survival.
Potential Benefits[edit | edit source]
The potential benefits of miproxifene phosphate include its ability to selectively target estrogen receptors in breast tissue while minimizing effects on other tissues, such as the endometrium and bone. This selectivity may lead to a better side effect profile compared to other antiestrogens.
Side Effects[edit | edit source]
As with other SERMs, miproxifene phosphate may cause side effects, including hot flashes, nausea, and an increased risk of thromboembolic events. However, its design aims to reduce the incidence and severity of these adverse effects compared to older agents.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
